The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer.

中文翻译：

---

在铂敏感复发性卵巢癌的 BRCA 非突变患者中使用帕博利珠单抗和贝伐珠单抗维持奥拉帕利的单臂 II 期研究 (OPEB-01)。

BRCA野生型铂敏感复发性卵巢癌患者的最佳治疗方案仍然未知。最近，越来越多的证据支持聚（二磷酸腺苷-核糖）聚合酶抑制剂、抗血管生成药物和免疫疗法的组合作为铂敏感复发的BRCA野生型患者的维持治疗。我们假设在奥拉帕利维持治疗中加入派姆单抗和贝伐单抗可以提高BRCA野生型铂敏感复发性卵巢癌患者的无进展生存期 (PFS) 。